Archive for January, 2009

Business Wire - Data Analysis Showed VYTORIN® Significantly Reduced LDL ”bad” Cholesterol and C-reactive Protein in Patients with High Cholesterol Compared to…

Saturday, January 10th, 2009

ATLANTA — In a new analysis presented today VYTORIN(R) (ezetimibe/simvastatin) significantly reduced LDL “bad” cholesterol by an average of 52.5 percent and C-reactive protein (CRP) by an average of 31.0 percent, compared to averages of 38.0 percent and 14.3 percent, respectively, achieved with Zocor(R) (simvastatin) (p

Related Results

New indication approved for ZocorNew zocor labelingNew Zocor labelingGeneric Zocor to debutGeneric Zocor …

Chain Drug Review - Questions on Vytorin Mount

Wednesday, January 7th, 2009

WASHINGTON — A congressional committee investigating whether the marketers of the cholesterol drug Vytorin withheld data that would hurt sales has released new evidence that critics contend supports such suspicions. The Senate Finance Committee noted that even the researcher who led a crucial study of the drug accused Vytorin partners Merck & Co. and Schering-Plough Corp. of holding back negati…